Skip to main content
Subscribe
  • Login
  • My Account
  • Logout
  • Register For Free
  • Subscribe
  • News
    • Current News
    • Providers
    • Insurance
    • Government
    • Finance
    • Technology
    • Safety & Quality
    • Digital Health
    • Transformation
    • ESG
    • People
    • Regional News
    • Digital Edition (Web Version)
    • Patients
    • Operations
    • Care Delivery
    • Payment
    • Midwest
    • Northeast
    • South
    • West
  • Blogs
    • AI
    • Deals
    • Layoff Tracker
    • HLTH 2024
    • Sponsored Content: Vital Signs Blog
  • Opinion
    • Letters
    • From the Editor
  • Events & Awards
    • Awards
    • Conferences
    • Galas
    • Virtual Briefings
    • Webinars
    • Nominate/Eligibility
    • 100 Most Influential People
    • 50 Most Influential Clinical Executives
    • 40 Under 40
    • Best Places to Work in Healthcare
    • Healthcare Marketing Impact Awards
    • Innovators Awards
    • Diversity Leaders
    • Leading Women
    • Best in Business Awards
    • The 2030 Playbook Conference
    • Innovations in Patient Experience
    • Leading Women Conference & Awards Luncheon
    • Leadership Summit
    • Workforce Summit
    • Best Places to Work Awards Gala
    • Diversity Leaders Gala
    • - Looking Ahead to 2025
    • - Financial Growth
    • - Hospital of the Future
    • - Value Based Care
    • - Looking Ahead to 2026
  • Multimedia
    • Podcast - Beyond the Byline
    • Sponsored Podcast - Healthcare Insider
    • Sponsored Video Series - One on One
    • Sponsored Video Series - Checking In with Dan Peres
  • Data & Insights
    • Data & Insights Home
    • Hospital Financials
    • Staffing & Compensation
    • Quality & Safety
    • Mergers & Acquisitions
    • Skilled Nursing Facilities
    • Data Archive
    • Resource Guide: By the Numbers
    • Surveys
    • Data Points
  • Newsletters
  • MORE+
    • Contact Us
    • Advertise
    • Media Kit
    • Jobs
    • People on the Move
    • Reprints & Licensing
    • Sponsored Content
MENU
Breadcrumb
  1. Home
  2. Politics & Policy
April 22, 2021 12:05 PM

House Democrats back Medicare drug price negotiations in infrastructure talks

Jessie Hellmann
  • Tweet
  • Share
  • Share
  • Email
  • More
    Reprints Print
    Modern Healthcare Illustration / Getty Images

    House Democrats introduced a bill Thursday that would allow the federal government to negotiate with pharmaceutical companies for lower prices on drugs covered by Medicare, a long-held goal for the party that has its best chance in passing Congress in years.

     

    Still, substantial drug pricing reform appears to be an uphill battle with Democrats' narrow majorities in the House and Senate, mixed signals on whether President Joe Biden is ready to back such legislation this year, and lobbying by the powerful pharmaceutical industry.

     

    House Speaker Nancy Pelosi (D-Calif.) has said some version of the bill, called HR3, will be included in the infrastructure bill Congress is working on, but she is facing pushback from Republicans and some moderate Democrats, complicating the path forward.

     

    While Pelosi said she wants infrastructure to be bipartisan, Republicans oppose Medicare price negotiation, and moderate Democrats like Sen. Joe Manchin (D-W.Va.) have chafed at using reconciliation again to subvert the Senate filibuster and bypass the need for bipartisan support.

     

    Under current law, the federal government cannot have a direct role in negotiating or setting prices for drugs covered by Medicare Part B and D. The provision was meant to promote competition in the free market, but Democrats argue it does the opposite by allowing drug companies to raise prices because it knows Medicare must accept it.

     

    "The days of unfair price gouging of Americans at the pharmacy counter must come to an end," the chairmen of three House committees with jurisdiction over healthcare issues said in a statement Thursday.

     

    "This legislation will dramatically rein in costs and finally empower the federal government to negotiate fair prescription drug prices, decrease consumers' out-of-pocket costs, and reduce Medicare and private health insurance premiums," said Rep. Frank Pallone (D-N.J.), chair of the Energy & Commerce Committee, Richard Neal (D-Mass.), chair of the Ways & Means Committee, and Bobby Scott (D-Va.), chair of the Education & Labor Committee.

     

    The bill would require the HHS secretary to negotiate prices for a selected group of drugs, with new prices not exceeding 120% of the average prices paid by six other countries, including Australia and Canada. Those negotiated prices would also be made available to commercial health insurance plans.

     

    An analysis by the nonpartisan Congressional Budget Office of a previous version of the drug pricing bill estimated that the negotiation provision would save the federal government $450 billion over 10 years. Those savings entice Democratic leadership to include it in the infrastructure package so it can be used to pay for other priorities, like making permanent changes to Affordable Care Act subsidies.

     

    But while Biden ran for president on allowing Medicare to negotiate drug prices, rumors swirled in Washington this week that the second half of his infrastructure and jobs bill, which is expected to be released this month and touch on healthcare issues, will make no mention of drug pricing reform.

     

    Biden's proposals are meant as high-level guidance for Congress as it pieces together what's expected to be a multitrillion-dollar infrastructure package.

     

    "We look forward to working with the Biden administration to pass this critical legislation to lower the soaring cost of prescription drugs for the people," the committee chairmen said in a statement.

     

    Congress doesn't need a green light from Biden to include drug pricing provisions in the package, but it certainly helps as some moderate Democrats have expressed concern recently about Medicare price negotiation and its impact on innovation in the industry.

     

    Pharmaceutical companies argue their profits are poured back into research and development of new drugs, and point to the COVID-19 vaccines that were brought to the market in only a year.

     

    If drug companies make less money that could lead to fewer new drugs being introduced, they argue.

     

    The CBO report found the bill could result in eight fewer drugs coming to market over a 10-year period.

     

    But supporters of price negotiation argue those drugs are likely modest improvements over ones already on the market and that most breakthroughs are funded and developed by the federal government.

     

    Pelosi noted Thursday that drug companies have been profitable during the pandemic and Americans are still paying "three times more for prescription drugs for the very same drugs that are sold at one-third of that cost overseas."

     

    The bill would also provide billions of funding to National Institutes of Health for biomedical research.

     

    Pelosi has indicated some version of HR3 will be included in an infrastructure package Congress is working on, which they say they want to be bipartisan.

     

    But Republicans are unlikely to support price negotiation, which they call government price controls.

     

    Republicans are mostly opposed to the price negotiation provision, but there are some parts of HR3 that could have bipartisan support.

     

    It would cap out-of-pocket drug costs for seniors at $2,000 per year and require drug companies pay a rebate back to the federal government if their prices increase faster than inflation. Both of those provisions are similar to a bill introduced last year by Sens. Ron Wyden (D-Ore.) and Chuck Grassley (R-Iowa) .

    Letter
    to the
    Editor

    Send us a letter

    Have an opinion about this story? Click here to submit a Letter to the Editor, and we may publish it in print.

    Recommended for You
    mh-202550516-Chip-Roy
    Conservatives stall Medicaid-cutting budget, seek more savings
    mh-20250515-Buddy-Carter
    PBM limits could finally pass, if Congress moves its tax-cut bill
    Most Popular
    1
    UnitedHealth under criminal investigation for Medicare fraud: WSJ
    2
    States, providers face brunt of GOP Medicaid cuts plan
    3
    UnitedHealth Group to cut Medicare drug plan commissions
    4
    Federal dementia pilot has rocky rollout for some providers
    5
    'Legendary' Hemsley takes over at UnitedHealth amid rough seas
    Sponsored Content
    Modern Healthcare Alert: Sign up for this breaking news email to be kept in the loop as urgent healthcare business news unfolds.
    Get Newsletters

    Sign up for enewsletters and alerts to receive breaking news and in-depth coverage of healthcare events and trends, as they happen, right to your inbox.

    Subscribe Today
    MH Magazine Cover

    MH magazine offers content that sheds light on healthcare leaders’ complex choices and touch points—from strategy, governance, leadership development and finance to operations, clinical care, and marketing.

    Subscribe
    Connect with Us
    • LinkedIn
    • Twitter
    • Facebook
    • RSS

    Our Mission

    Modern Healthcare empowers industry leaders to succeed by providing unbiased reporting of the news, insights, analysis and data.

    Contact Us

    (877) 812-1581

    Email us

     

    Resources
    • Contact Us
    • Help Center
    • Advertise with Us
    • Ad Choices
    • Sitemap
    Editorial Dept
    • Submission Guidelines
    • Code of Ethics
    • Awards
    • About Us
    Legal
    • Terms and Conditions
    • Privacy Policy
    • Privacy Request
    Modern Healthcare
    Copyright © 1996-2025. Crain Communications, Inc. All Rights Reserved.
    • News
      • Current News
      • Providers
      • Insurance
      • Government
      • Finance
      • Technology
      • Safety & Quality
      • Digital Health
      • Transformation
        • Patients
        • Operations
        • Care Delivery
        • Payment
      • ESG
      • People
      • Regional News
        • Midwest
        • Northeast
        • South
        • West
      • Digital Edition (Web Version)
    • Blogs
      • AI
      • Deals
      • Layoff Tracker
      • HLTH 2024
      • Sponsored Content: Vital Signs Blog
    • Opinion
      • Letters
      • From the Editor
    • Events & Awards
      • Awards
        • Nominate/Eligibility
        • 100 Most Influential People
        • 50 Most Influential Clinical Executives
        • 40 Under 40
        • Best Places to Work in Healthcare
        • Healthcare Marketing Impact Awards
        • Innovators Awards
        • Diversity Leaders
        • Leading Women
        • Best in Business Awards
      • Conferences
        • The 2030 Playbook Conference
        • Innovations in Patient Experience
        • Leading Women Conference & Awards Luncheon
        • Leadership Summit
        • Workforce Summit
      • Galas
        • Best Places to Work Awards Gala
        • Diversity Leaders Gala
      • Virtual Briefings
        • - Looking Ahead to 2025
        • - Financial Growth
        • - Hospital of the Future
        • - Value Based Care
        • - Looking Ahead to 2026
      • Webinars
    • Multimedia
      • Podcast - Beyond the Byline
      • Sponsored Podcast - Healthcare Insider
      • Sponsored Video Series - One on One
      • Sponsored Video Series - Checking In with Dan Peres
    • Data & Insights
      • Data & Insights Home
      • Hospital Financials
      • Staffing & Compensation
      • Quality & Safety
      • Mergers & Acquisitions
      • Skilled Nursing Facilities
      • Data Archive
      • Resource Guide: By the Numbers
      • Surveys
      • Data Points
    • Newsletters
    • MORE+
      • Contact Us
      • Advertise
      • Media Kit
      • Jobs
      • People on the Move
      • Reprints & Licensing
      • Sponsored Content